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Abstract
Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the DMD gene and loss of the
protein dystrophin. The absence of dystrophin leads to myofiber membrane fragility and necrosis, with eventual muscle
atrophy and contractures. Affected boys typically die in their second or third decade due to either respiratory failure or
cardiomyopathy. Despite extensive attempts to develop definitive therapies for DMD, the standard of care remains
prednisone, which has only palliative benefits. Animal models, mainly the mdx mouse and golden retriever muscular
dystrophy (GRMD) dog, have played a key role in studies of DMD pathogenesis and treatment development. Because
the GRMD clinical syndrome is more severe than in mice, better aligning with the progressive course of DMD, canine
studies may translate better to humans. The original founder dog for all GRMD colonies worldwide was identified in the
early 1980s before the discovery of the DMD gene and dystrophin. Accordingly, analogies to DMD were initially drawn
based on similar clinical features, ranging from the X-linked pattern of inheritance to overlapping histopathologic
lesions. Confirmation of genetic homology between DMD and GRMD came with identification of the underlying GRMD
mutation, a single nucleotide change that leads to exon skipping and an out-of-frame DMD transcript. GRMD colonies
have subsequently been established to conduct pathogenetic and preclinical treatment studies. Simultaneous with the
onset of GRMD treatment trials, phenotypic biomarkers were developed, allowing definitive characterization of treatment
effect. Importantly, GRMD studies have not always substantiated findings from mdx mice and have sometimes identified
serious treatment side effects. While the GRMD model may be more clinically relevant than the mdx mouse, usage has
been limited by practical considerations related to expense and the number of dogs available. This further complicates
ongoing broader concerns about the poor rate of translation of animal model preclinical studies to humans with
analogous diseases. Accordingly, in performing GRMD trials, special attention must be paid to experimental design to
align with the approach used in DMD clinical trials. This review provides context for the GRMD model, beginning with its
original description and extending to its use in preclinical trials.
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Background
Duchenne muscular dystrophy (DMD) is a devastating X-
linked inherited degenerative muscle disease [1] affecting
~1 in 4000–6000 boys [2]. Mutations in the DMD gene
limit production of the protein, dystrophin, resulting in loss
of myofiber membrane integrity and repeated cycles of ne-
crosis and regeneration [1]. Muscle is gradually replaced
with fibrous connective tissue and fat, leading to weakness
and debilitating contractures. Eventual involvement of
respiratory muscles and the heart causes cardiopulmonary
failure and death in the second to third decade of life.
Although the molecular basis for DMDwas defined 30 years
ago, glucocorticoids and supportive therapy remain the
standard of care.
Prior to the discovery of the DMD gene and dys-
trophin protein in the 1980s, there were no definitive
genetic animal models for DMD. Various inherited and
experimental primary myopathies in animals, most not-
ably in mice, chickens, and hamsters, were studied in an
effort to gain insight into the pathogenesis and potential
treatment of the human dystrophies [3]. The most obvi-
ous discrepancy in these models related to their
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autosomal versus X-linked pattern of inheritance. While
these animal studies provided useful insight on disease
pathogenesis, their overall value was questioned [4].
Subsequently, spontaneous genetically homologous
dystrophinopathies have been identified in several mam-
malian species, including mice and dogs. Because the
phenotype of dystrophic dogs more closely mirrors that
of DMD, pathogenetic and preclinical treatment studies
may better translate to humans. Most canine studies
have been conducted in the golden retriever muscular
dystrophy (GRMD) model, which occurs due to a spon-
taneous splice site mutation in the DMD gene. In this
review, fundamental early observations that hinted at
the membranal nature of both DMD and GRMD are
covered first, followed by a discussion of molecular stud-
ies that identified the DMD gene and dystrophin protein.
Challenges facing physicians and scientists in translating
therapies from animals to humans are then discussed,
with emphasis on the importance of first and foremost
establishing safety. The review concludes with an over-
view of the role of animal models and, in particular,
GRMD in treatment development.
Disease pathogenesis: the membrane theory
Well before the molecular age allowed identification of
disease-causing genes, physicians and scientists relied on
clinical clues and their intuition to infer disease pathogen-
esis. Much early attention focused on the so-called mem-
brane theory of DMD, as stated by Rowland, “The
functional genetic fault of DMD affects an enzyme or
structural protein which is decreased in amount or ren-
dered functionally abnormal because of an altered amino
acid sequence. In either case, the altered protein results in
abnormal composition and altered function of muscle cell
surface membranes” [4]. The membrane theory originated
with the observation that enzymes, such as aldolase and
phosphorylase, were decreased in muscle [5] and elevated
in serum [6, 7]. This was presumed to occur because of
damage to the myofiber membrane, the sarcolemma. In
fact, elevations of creatine phosphokinase (CPK), now typ-
ically shortened to creatine kinase (CK), had become
particularly useful in the diagnosis of DMD [6]. Additional
support for the membrane theory came from ultrastruc-
tural studies showing defects in the sarcolemma (Fig. 1)
that purportedly allowed enzyme leakage [8–11]. Con-
comitant influx of calcium was hypothesized to lead to
fiber hypercontraction or protease activation, each of
which could contribute to the characteristic myofiber
(hyaline) necrosis seen in DMD. In support of this mech-
anistic disease association, the membrane lesions some-
times overlay wedge-shaped areas of focal necrosis, so
called delta lesions [10] (see Fig. 4).
In addition to enzyme changes and sarcolemma le-
sions, electromyography (EMG) provided a third less
discussed marker of potential membrane involvement. As
with other myopathies, DMD is characterized by low ampli-
tude, short-duration motor unit potentials, with associated
spontaneous activity ranging from fibrillation potentials to
complex repetitive discharges (CRDs) [12–15]. The occur-
rence of CRDs is of particular interest, given their pre-
dominance on EMG studies in canine dystrophinopathies
(see below). Previously called pseudomyotonia or bizarre
high-frequency discharges, CRDs are high frequency spon-
taneous potentials that begin and end abruptly [16, 17]
(Fig. 2). This pattern contrasts with true myotonic discharges
that wax and wane, creating a characteristic “dive bomber”
sound [17]. While spontaneous activity on EMG may occur
with either neuropathies or myopathies, CRDs occur prefer-
entially in myopathies [18] and point to myofiber membrane
involvement [19]. Buchtral and Rosenfalck reported pseudo-
myotonic bursts in human progressive muscular dystrophy
patients in their 1963 monograph [12] (Fig. 2). Others have
shown that CRDs occur more often than additional forms of
pathologic spontaneous activity in DMD versus the less clin-
ically severe dystrophinopathy, Becker muscular dystrophy
(BMD) (see below), and even more so, when compared to
the other dystrophies [14, 15]. In general, CRDs are thought
to occur through ephaptic transmission of action potentials
between muscle fibers, although the involved mechanisms
are not well understood [17, 20]. In principle, membrane le-
sions that limit chloride or enhance sodium conductance
into the myofiber could shift the resting membrane potential
towards the threshold for depolarization, with associated re-
petitive electrical discharges [21]. Consistent with this obser-
vation, mutations in chloride (CLCN1) and sodium
(SCN4A) skeletal muscle channel genes have been incrimi-
nated in the myotonias [16]. Moreover, dysregulation of
NaV1.4, the protein product of SCN4A, leads to increased
intracellular sodium and cell death in mdx mice [22], which
also express CRDs [23, 24].
Fig. 1 Characteristic myofiber membrane lesion in DMD. Electron
photomicrograph demonstrates lack of continuity of the myofiber
(sarcolemmal) membrane (arrows), while the basal lamina remains
intact. The myofiber architecture is disrupted subjacent to the
membrane lesion. Original magnification 26,000. From reference [8]
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The DMD gene, dystrophin protein, and
dystrophin-glycoprotein complex
The mode of inheritance for DMD was long suspected
to be X-linked because of the disease’s predominance in
males. While an X-linked pattern was ultimately corrob-
orated by pedigree studies [25, 26], this interpretation
was clouded by the rare occurrence of a similar clinical
syndrome in girls [27]. Some such cases were thought to
occur due to disproportionate inactivation of the normal
X chromosome in female DMD carriers, as was subse-
quently well documented [28]. Others were associated
with autosomal translocations within the Xp21 region of
the short arm of the X-chromosome, pointing to this
area as a likely site of the DMD gene [29]. This putative
site was confirmed when restriction fragment length
polymorphisms (RFLPs; markers) cleaved from DNA
were shown to flank the Xp21 locus [30]. An analogous
association was made with the less severe clinical syn-
drome of BMD [31]. Following closely on this work,
Kunkel et al. capitalized on a DMD patient with a cyto-
genetically visible Xp21 deletion that also included genes
for three other diseases [32, 33]. Several DNA fragments
absent from the patient were cloned to provide linkage
markers for the DMD locus. In a follow-up multicenter
study, DNA from over a thousand DMD and BMD
patients was probed using these clones, with 6.5% show-
ing deletions at the DXS21 locus [34]. Using the DXS21
locus as the starting point, chromosomal walking was
employed to map and clone the entire 14 kb DMD gene
transcript [35]. Dystrophin, the 425 kd protein product
of the DMD gene, was characterized and found to be ab-
sent in both DMD patients and the mdx mouse [36].
Tying matters together further, the molecular basis for
DMD and BMD was shown to depend on whether the
underlying mutation maintained (BMD; in frame) or dis-
rupted (DMD; out of frame) the three nucleotide (codon)
reading frame for amino acids [37]. Subsequent studies
have established that deletions (60%) and duplications
(5%) account for ~65% of DMD and BMD mutations and
that they tend to concentrate in two so-called hot spot
areas near the N-terminus (exons 3-7) and within the cen-
tral rod domain (exons 45-53) [38–41]. Definition of the
specific extent and location of the mutation has become
critical with the advent of antisense oligonucleotide ther-
apies intended to reestablish the reading frame (see below
in the context of canine DMD gene mutations) [42]. In
tandem with early studies of the DMD gene, Campbell
and Kahl published work that led to a series of compre-
hensive studies linking dystrophin with additional proteins
and sugar moieties to form the dystrophin-glycoprotein
complex [43]. A number of other muscular dystrophies
subsequently have been causally associated with mutations
in genes coding for structural proteins and glycosylating
enzymes within this complex [44, 45].
The search for a cure
The approach to DMD treatment can be divided into
two periods. The first predated identification of the
DMD gene and dystrophin protein when management
was largely symptomatic or employed drugs directed at
disease mechanisms inferred from pathologic changes.
Extending from this period, the second phase has fo-
cused on directed genetic and cellular approaches that
offer the potential for cure. Soon after the discovery of
the DMD gene and dystrophin protein, the “Journal of
Child Neurology” published three perspectives from Jan
Witkowski [46], Victor Dubowitz [47], and Jerry Lewis
[48], the first two commenting as a scientist and clin-
ician and Mr. Lewis as a longstanding champion for the
Muscular Dystrophy Association and “Jerry’s Kids.” Key
comments from each of their commentaries are repro-
duced here:
Fig. 2 Spontaneous EMG activity in muscle disease. Activity, termed pseudomyotonic bursts, that begins and ends abruptly, in the hypertrophied
calf muscle of a DMD patient (a, b), contrasts with waxing and waning myotonic activity from a forearm extensor of a myotonic dystrophy
patient (c, d). The activity in a was recorded from two fibers discharging at 22 and 11/s over a 45-s period with the three bursts (a–c) separated
by 20 s. Bursts in b had a frequency of 15/s. Increasing and decreasing activity in c (maximum 50/s) and d (maximum 35/s) were induced by
movement of the concentric recording electrode and direct stimuli, respectively. From reference [12]
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This new knowledge has tremendous implications for
the physician caring for DMD patients and their
families, and it has led to new methods for diagnosis,
prognosis, and genetic counseling. In the not-too-
distant future, this research may lead to therapies for
DMD. Jan Witkowski
Although it may be exciting to speculate on the
possibility of gene therapy in muscular dystrophy, it
seems extremely unlikely that this could become a
reality in the foreseeable future. Victor Dubowitz
I don’t pretend to understand the language of science
or comprehend the many complex research findings
discussed in these articles. But there’s a basic,
underlying message I do understand – a message of
excitement that we’ve scored long-awaited victories
against a disease that cripples and kills thousands of
children, and of hope that these victories will soon
lead us to a cure or a treatment. Jerry Lewis
Reflecting on these comments in hindsight garnered
over 30 years, each appears to have gotten things just
about right. As Dr. Witkowski predicted, the discovery of
the DMD gene and dystrophin protein has advanced the
fields of diagnosis and genetic counseling and set the stage
for more directed DMD treatments, to include gene and
cell-based approaches. And, who could argue with Jerry
Lewis, who pointed to the tremendous energy that these
discoveries unleashed. But, Dr. Dubowitz’s cautionary note
was also prophetic. Progress on genetic therapies has been
frustratingly slow, with a number of approaches failing or
being delayed by unforeseen complications. The fact that
glucocorticoids remain the standard of care for DMD pro-
vides stark evidence of the challenges of implementing
genetic and cellular therapies [49, 50].
The long and winding road to drug approval
The road to drug approval is often difficult, with less than
20% of Phase II trials being successful, typically due to ei-
ther a lack of efficacy or safety concerns [51, 52]. Failure to
demonstrate efficacy is caused, in part, by challenges in ac-
cruing sufficient patients to achieve necessary power [53].
This issue is exaggerated with rare (orphaned) diseases such
as DMD. The Orphan Drug Act of 1983 provided various
Food and Drug Administration (FDA) incentives, including
expedited review and delayed approval of competing
drugs, to facilitate development of therapeutics [54].
Motivated by these incentives, there has been a
marked uptick in approaches directed at Duchenne
patients. A total of 206 studies of DMD diagnostic
tests and treatment trials in various stages of initial en-
rollment to termination are currently listed on the NIH
Clinical Trials.gov website (https://clinicaltrials.gov/ct2/
results?term=Duchenne+Muscular+Dystrophy&pg=2).
Results of these new treatments have been mixed [49].
On a promising note, ataluren, the first drug approved to
specifically target the underlying DMD gene mutation,
showed potential benefit in an initial phase 2b study [55,
56] and patients are now being enrolled in a larger phase
3-trial (https://clinicaltrials.gov/ct2/show/NCT02090959?
term=ataluren&rank=1). However, other recent clinical
trials, including the failure of phophodiester-5 inhibitors
to translate to Duchenne and Becker patients [57, 58] and
ongoing questions surrounding efficacy of the exon-
skipping strategies [59, 60], have illustrated the com-
plexities surrounding treatment development.
Doctor, do no harm
In treating patients, physicians have been guided by a set
of ethical principles that date to ancient Greece and are
embodied in the Hippocratic oath. Indeed, some form of
this oath is taken by newly graduating physicians and
should guide all who practice clinical medicine. While
not specifically included in the original oath, newer
versions typically include language to the effect of, “first,
do no harm.” Safety also lies at the heart of the FDA's
approval process for an investigational new drug (IND),
as detailed in FDA Code of Federal Regulations
(CFR) Title 21, Part 312 (accessdata.fda.gov/scripts/
cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart = 312), begin-
ning with preclinical testing in animals and the subse-
quent phased process for human clinical trials. Smaller
populations of human volunteers are first evaluated to
establish safety (Phase 1) before larger clinical groups
are tested to determine efficacy (Phases 2-4).
Preclinical animal testing has played a critical role in
demonstrating drug safety, extending from FDA policies
formulated over the past 50 years to the IND protocol
used today. Acute, subacute, and chronic dosing studies
are required in a rodent and second (often dog) species
[61, 62]. For sake of pediatric populations, emphasis has
been placed on the use of analogous juvenile animals to
better predict potential developmental side effects (see
“GRMD in preclinical trials: experimental design” section
below) [63]. The FDA has also recently released rigorous
guidelines for gene and cell-based therapies [64, 65].
Germane to this review, these guidelines emphasize
choosing animal models likely to demonstrate a biological
response, such as immunity, that would be expected in
humans. Moreover, disease models were recommended
over normal animals because of their greater likelihood to
predict the risk-benefit ratio of the investigational product.
The golden retriever model
Animal models: an overview
Safety considerations discussed above point to the im-
portance of careful design of preclinical studies, to
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include animal model selection. In this regard, a 1985
National Research Council report emphasized that
biological modeling could be by either analogy or hom-
ology [66]. Analogy implies a point-by-point relationship
between one structure or process to another, while hom-
ology suggests a shared evolutionary history and match-
ing DNA makeup. Before the discovery of the DMD
gene in 1987, it was not possible to identify true genetic-
ally homologous animal models. Investigators had to rely
on models that were neither analogous phenotypically
nor genetically homologous [3]. Naturally occurring gen-
etic DMD mammalian models have subsequently been
defined in mice [67–69], dogs [70], cats [71, 72], and
pigs [73]. As would be expected, given inherent biologic
differences between quadruped animals and humans,
none of these mammalian DMD models are fully analo-
gous clinically. Most notably, mdx mice are mildly af-
fected, with near-normal life expectancy. Dystrophic cats
have a curious hypertrophic myopathy and are prone to
a malignant-hyperthermia like syndrome [74]. Dogs have
a severe phenotype that more closely mirrors that of
DMD. But, as discussed below, dystrophic dogs may
stabilize after ~6 months of age and often live well into
adulthood [75]. Although knockout and spontaneous
dystrophic pigs have not yet been fully characterized,
one knock out model had an unexpectedly severe
phenotype (Rogers C, personal communication, 2014).
The lack of analogy between the phenotypes of different
animal models and DMD inherently limits conclusions
that can be reached from mechanistic and preclinical
studies. A rat model, created by molecularly targeting
DMD gene exon 23, could have advantages over the
thus-far described mdx and larger spontaneous mamma-
lian models [76].
Potential DMD treatments have generally been tested
initially in the mdx mouse, often establishing proof of
concept for the particular approach [77]. Major advan-
tages of the mdx mouse include its consistent phenotype
and relatively modest expense, which allows multiple
variables to be tested through reasonably powered stud-
ies. On the other hand, the mouse’s small size limits
assessment of scalable variables such as cell migration or
drug diffusion [78]. Perhaps even more importantly,
mdx mouse preclinical trials have generally not identi-
fied treatment complications. This has been particularly
problematic with their failure to predict immunologic
side effects of gene and cell therapies. These advantages
and limitations are essentially reversed for dystrophic
dogs. Expense of maintaining dogs limits the number of
variables that can be tested and phenotypic variation fur-
ther reduces the power that can be achieved. With that
said, the dog’s larger size and outbred nature allows for
better modeling of scalable variables such as cell diffu-
sion and the immune response to biologics. A general
paradigm has evolved, whereby initial testing is done in
mdx mice and, pending positive results, follow-up stud-
ies in dystrophic dogs are considered.
Animal models: the two cultures of drug discovery
Considerable attention has recently been focused on the
failure of preclinical treatment trials to translate to hu-
man patients. Various reasons have been offered to ac-
count for this disconnect. A key factor relates to what
has been termed the “two cultures phenomenon” [79].
Put simply, preclinical studies are often as loose as clin-
ical trials are rigorous. Too little attention is paid to
basic tenets of experimental design, extending from
power analysis of the biomarker used to assess efficacy to
the need for blinding [80, 81]. This problem extends to
the level of detail provided on experimental design in
grant applications and also to the degree to which it is
considered in the review process. Understandably, the re-
view process places considerable emphasis on a proposal’s
innovative approach and potential impact. Unfortunately,
less attention is sometimes paid to experimental design.
Canine and other large animal models are particularly vul-
nerable in this area. Legitimate animal availability and
budgetary issues consistently preclude conduct of a perfect
study that is sufficiently powered and allows all variables
to be considered. Accordingly, large animal studies
must be focused and resist the temptation to explore
a tangential issue.
Animal models: a change in mindset
As detailed above, preclinical animal studies help to in-
form the drug discovery process for both efficacy and
safety. Safety is well represented in classical toxicologic
assays that demonstrate potential off-target effects of a
drug, as with hepatotoxicy. However, safety has often
taken a backseat to efficacy in preclinical treatment tri-
als. Investigators seem overly motivated to show that a
treatment “works” versus pointing out that it failed or
had deleterious consequences. Results that identify limi-
tations of a treatment are said to be “disappointing” and,
potentially, not even deserving of publication [81]. One
could argue that this is precisely the wrong attitude. The
greatest shortcoming of an animal model is not that it
failed to demonstrate efficacy but that it failed to identify
a potential risk. That it did not identify a worst-case sce-
nario that led to a set of serious side effects. Stated an-
other way, an animal model has failed when it did not
identify a risk that caused serious complications in the
131st patient in a phase 3 treatment trial after all had
gone well with the first 130. To address the apparent
disconnect between animal and human clinical studies,
preclinical investigators must be more rigorous in devel-
oping their experimental designs and place more import-
ance on identifying treatment complications.
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Dusty and Rusty
The GRMD model can be traced to a litter of golden
retrievers, three males and one female, born July 21,
1981, outside Athens, Georgia, the home of the Univer-
sity of Georgia. Stiffness and simultaneous advancement
of the pelvic limbs (bunny hopping) was noted in all
three males at 9–11 weeks of age. Clinical signs of
muscle disease were not seen in the dam, sire, or female
littermate or in previous or subsequent litters of the
dam. However, the same mating was purposely not re-
peated. A single male sibling from both the dam’s own
litter and that of the grand dam had similar clinical
signs. Cardinet and Holiday reported partial results from
histopathologic studies of the male sibling from the
dam’s litter in their 1979 monograph on canine muscle
disease [82]. The sibling from the grand dam’s litter was
euthanized after only a minimal evaluation and a nec-
ropsy was not done.
A veterinarian in private practice near Athens evalu-
ated the dogs and submitted blood for routine analysis
through the Veterinary Medical Diagnostic Laboratory at
the University of Georgia on September 29, 1981. The
most significant abnormality was dramatic elevation of
serum CK (U/l) in two of the males, Dusty (16,770) and
Rusty (24,442). Values for the other male (798) and fe-
male (529) were within normal limits. An inherited
degenerative myopathy was suspected, and the owners
were given a guarded prognosis. The male dog with the
normal CK value died acutely when it was 10 weeks old,
and a congenital diaphragmatic hernia compatible with
an apparently unrelated syndrome seen in golden
retrievers [83] was diagnosed at necropsy. Histopatho-
logic lesions were not seen on assessment of selected
skeletal muscles.
Dusty and Rusty were donated to the University of
Georgia Veterinary Teaching Hospital on October 16,
1981, with an understanding that breeding might be
done to perpetuate the condition. A series of tests, in-
cluding CBC, serum chemistries, EMG, and muscle
biopsies, were subsequently performed over the next
10 months. Results were compatible with a degenerative
myopathy that had previously been documented in five
other male golden retrievers (Table 1). The condition
was called “golden retriever myopathy,” in keeping with
a tendency for veterinarians to name canine diseases for
the breed in which they occur [84]. Dusty and Rusty
Table 1 Additional golden retrievers with degenerative myopathy as of 1988
Age at clinical
onset
Gender Clinical signs CK EMG Pathologic lesions Outcome Reference
10 days M Body stunting; glossal, shoulder,
and neck muscle hypertrophy;
bradycardia
NE NE Gross body stunting and
muscle hypertrophy. Skeletal
muscle histologic evidence of
variation in fiber size, hyaline
fibers with calcification, and
basophilia consistent with
regeneration; inflammation
including giant cells; milder
lesions in the heart.
Euthanasia
at 10 days
[88]
6–8 weeks
(two littermates
were described)
M Stiff gait with progression to a
stilted, shuffling gait by 3 months.
Fatigue with exercise, occasional
respiratory distress, neck stiffness,
resistance to jaw opening, and
glossal hypertrophy.
Elevated “Myotonia” Severe degenerative muscle
disease: myofiber necrosis,
mononuclear phagocytosis,
giant cells, and calcification
Euthanasia at
6–9 months
when the
dogs were still
ambulatory
[91]
4–5 months M Generalized muscle atrophy, stiff
gait, dysphagia, stenotic breathing,
exercise intolerance.
NE CRDs Gross muscle atrophy; scattered
necrotic fibers undergoing
phagocytosis, increased
endomysial connective tissue,
calcification of myofibers,
targetoid fibers, and fiber type
grouping; myocardial
degeneration and calcification
8 months at
biopsy; outcome
not given.
[82]
8 weeks M Stiff, shuffling gait; simultaneous
pelvic limb advancement (bunny
hopping); overextension at the
carpus, overflexion at the tarsus,
and abduction of the paws; stifle
adduction; hypertrophy of
proximal limb muscles; mild
vertebral kyphosis; trismus;
drooling.
13,435 IU/
l
CRDs and
positive
sharp
waves
4 months: fiber size variation,
hyaline and necrotic fibers with
myophagocytosis; centrally
nucleated fibers; basophilic
fibers consistent with
regeneration. 8 months:
progressive changes with
mineralization and endoymysial
and perimysial fibrosis; fibers
with chains of central nuclei;
fiber grouping.
Euthanasia at
8 months
[93]
Kornegay Skeletal Muscle  (2017) 7:9 Page 6 of 21
were moved to the College of Veterinary Medicine at
North Carolina State University (NCSU) in the Fall of
1982 for continued assessment. Longitudinal phenotypic
studies on these dogs up to 27 and 40 months of age at
Georgia and NCSU were reported [85]. Briefly, serum
CK was dramatically elevated (>10,000 U/l) and there
were features of both muscle fiber degeneration (hyaline
fibers, myophagocytosis) and regeneration (small baso-
philic fibers) on light microscopy. Persistent spontan-
eous high-frequency discharges, termed pseudomyotonia
in our original paper, were seen on EMG.
Rusty (Fig. 3) was moved to the College of Veterinary
Medicine at Cornell University at 41 months of age
(see below). Clinical and pathologic data collected until
his death at 6 years have been published [86, 87].
Early reports of golden retrievers with apparent
myopathy (Table 1)
Meier described a 10-day-old male golden retriever with
an apparent myopathy in a monograph on canine
muscle disease in 1958 [88]. The dog was born with an
enlarged tongue that became bigger over time and
“crowded the oral cavity and interfered with normal res-
piration and nursing.” Bradycardia and gross enlarge-
ment of the muscles of the neck and shoulders were
identified on clinical examination. The most striking
features at necropsy were body stunting and muscle
hypertrophy. Variation in myofiber size, hyaline fibers
with calcification, and myofiber basophilia consistent
with regeneration were noted microscopically. Milder le-
sions were seen in the heart. There was a remarkable in-
flammatory cell infiltrate that included histiocytes and
giant cells. Meier speculated that the findings were consist-
ent with vitamin E deficiency at birth. Obviously, one can-
not say definitively that this dog had a dystrophinopathy.
While muscle hypertrophy, especially involving the tongue,
is a feature of both DMD and GRMD, generalized muscle
enlargement from birth is unprecedented in my experi-
ence. Otherwise, this dog bears some resemblance to the
fulminant form of disease reported by Valentine et al. [86]
and seen by others, in which respiration is compromised at
birth. This condition may be analogous to pulmonary hy-
poplasia seen with congenital diaphragmatic hernia in
humans [89]. Normal lung development is dependent on
contractile activity of the diaphragm [90] so would likely
be compromised in severely affected GRMD fetuses.
Alexander (Sandy) deLahunta provided clinical data on
two male golden retrievers evaluated at Cornell University
in his 1977 textbook, Veterinary Neuroanatomy and
Clinical Neurology [91]. The syndrome was discussed
together with a similar condition in Irish Terriers (see
below) under a subheading of “Hereditary Myotonic My-
opathy in Puppies.” Stiff gait was seen at 6 to 8 weeks of
age, with progression to a stilted, shuffling gait by
3 months. Other clinical features included fatigue with
exercise, occasional respiratory distress, neck stiffness, re-
sistance to jaw opening, and enlargement of the base of
the tongue. The dogs were still able to walk at 6 to
9 months when euthanasia was performed. Additional key
findings included elevation of serum muscle enzymes,
“myotonia” on EMG, and evidence of “severe degenerative
muscle disease” on muscle biopsy or necropsy (necrosis of
muscle cells, mononuclear phagocytosis, giant cells, and
calcification). Reference was made to the more thoroughly
studied condition in Irish Terriers, which had been shown
by pedigree analysis to be X-linked [92] (see below).
Cardinet and Holliday described an additional 8-month-
old golden retriever dog in 1979 [82]. Clinical features
were consistent with those described by deLahunta. High-
frequency discharges that waxed and waned were seen on
EMG. Histopathologic features included scattered nec-
rotic and/or calcified fibers. Cardinet and Holliday noted
that fiber type grouping was consistent with a potential
neuropathic component. Another dystrophic golden re-
triever with similar clinical signs was subsequently identi-
fied at Cornell and studied until 8 months of age [93].
Muscle ultrastructure was studied for the first time. Not-
ably, focal wedge-shaped subsarcolemmal “delta” lesions
and plasma membrane defects were illustrated (Fig. 4), in
keeping with the membrane theory of DMD pathogenesis.
Thus, counting Rusty and Dusty, a total of seven
golden retrievers with an apparent primary, inherited
myopathy had been reported by the mid-1980s (Table 1).
Additional dogs were cited via personal communication
in our 1988 paper [85]. Strikingly, all affected golden re-
trievers were males, suggesting X-linked inheritance and
potential genetic homology with DMD. Clinicopatho-
logic evidence of serum CK elevation and small group
muscle fiber necrosis and regeneration were also
Fig. 3 GRMD colony founder dog, Rusty, at North Carolina State
University at ~3 years of age. Note the relatively mild phenotype
characterized primarily by a plantigrade stance
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consistent with DMD. On the other hand, presence of
CRDs on EMG, with associated stilted gait, stiffness, and
marked muscle hypertrophy, were more consistent with
myotonia.
Cornell and canine X-linked muscular dystrophy
As detailed above, deLahunta and colleagues at Cornell
played a key role in identifying early dystrophic golden
retrievers. Barry Cooper, in particular, was motivated to
establish a breeding colony of affected dogs and was
aware of ongoing studies at NCSU. Rusty was sent to
Cornell at 41 months of age, with an understanding that
he would be used to establish a colony and then
returned for follow on studies at NCSU. However, Rusty
developed congestive heart failure at 5½ years of age and
was euthanized at 6 years. So, instead, two obligate car-
riers (Dys and Trophy) and an affected male (Lewis)
produced by Rusty were provided to NCSU to establish
a second colony.
The studies by Dr. Cooper and his veterinary col-
league, Beth Valentine, were instrumental in defining the
phenotype of dystrophic dogs [86, 87, 94]. Rusty was ini-
tially bred with two female beagles and a larger retriever
cross to produce mixed-breed obligate carriers. These
carriers were then bred with Rusty or his male descen-
dants to produce affected dogs. In this sense, GRMD is
not a disease of pure-bred golden retrievers. We use the
GRMD acronym to refer to the DMD gene splice site
mutation present in affected dogs. Other acronyms, such
as GSHPMD for German shorthaired pointer muscular
dystrophy, refer to additional canine DMD gene muta-
tions. Based on pedigree analysis of the dogs descendant
from Rusty at Cornell, a likely recessive X-linked pattern
of inheritance was established [95]. Phenotypic features
in dogs from the Cornell colony were consistent with
those reported in the previously described seven cases
and included elevation of serum CK, CRDs on EMG,
and histopathologic evidence of grouped muscle fiber
necrosis and regeneration. Because this work was done
before the DMD gene and dystrophin protein were iden-
tified, there was still a question as to whether the disease
was a Duchenne genetic homologue. Genetic homology
was established with reasonable certainly when neither
DMD messenger ribonucleic acid (mRNA) nor dys-
trophin could be identified in dystrophic dogs [94]. Con-
sistent with the GRMD site splice mutation later
identified by Sharp et al. [96] (see below), endonuclease
probes did not demonstrate RFLPS that would be
expected with a large DNA deletion. Cooper and col-
leagues termed the disease canine X-linked muscular
dystrophy (CXMD).
Canine dystrophinopathies
Prior to the definition of the DMD gene and dystrophin
protein, potentially analogous canine models were pro-
posed based on an apparent pattern of recessive X-
linked inheritance and consistent phenotypic features. In
his 1977 textbook [91], deLahunta drew parallels be-
tween the condition in golden retrievers and an analo-
gous disease in Irish terrier dogs reported by Wentink et
al. [92]. The Irish terrier study included phenotypic data,
extending from serum enzymes to necropsies, on a
group of five male littermates. Pedigree data, suggesting
a pattern of recessive X-linked inheritance, were re-
ported from two prior litters from the same bitch. Serum
enzymes, including aldolase and CK, were elevated, in
keeping with the membrane theory of DMD pathogen-
esis. Wentink et al. specifically noted that the dramatic
Fig. 4 Myofiber with focal necrosis and membrane lesion in GRMD dog. Electron photomicrographs demonstrating a wedge-shaped subsarcolemmal
area of disrupted architecture (a) and higher magnification (b) of the area identified with the asterisk where the myofiber membrane is absent (arrow)
and the basal lamina is intact. Original magnification 4500 in a and 13,500 in b. Modified from reference [93]
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increase in CK was typical of DMD. Bizarre high-
frequency discharges were seen on EMG, consistent with
other canine dystrophinopathies that have since been
characterized. Notably, dogs were variably affected, with
two having a severe phenotype that necessitated euthan-
asia between 13 and 20 weeks of age, while another
mildly affected dog lived until 16 months before euthan-
asia. Limb muscles were atrophied but the tongue was
hypertrophied. One of the dogs had congenital perito-
neopericardial diaphragmatic hernia at necropsy consist-
ent with a syndrome later seen in GRMD dogs.
Histopathological lesions were not seen in the hearts,
central nervous system, or visceral organs of affected
dogs. Based on extensive muscle histochemical and
ultrastructural studies, Wentink et al. concluded that
mitochondria were abnormal and speculated that
uncoupled oxidative phosphorylation could be involved
in disease pathogenesis.
Additional apparent dystrophinopathies have since been
reported in a number of canine breeds [70, 96–105]
(Fig. 5). Phenotypic findings, typical of those seen in
GRMD, have included increased serum CK, CRDs on
EMG, and histopathologic evidence of grouped muscle
fiber necrosis and regeneration. When multiple dogs have
been observed, disease severity has varied, in keeping with
phenotypic variation seen in GRMD. As with GRMD,
paradoxical muscle hypertrophy has seemed to play a role
in the phenotype of affected dogs, with stiffness at gait,
decreased joint range of motion, and trismus being
common features. For the most part, dystrophinopathies
in other canine breeds have not been defined beyond
immunohistochemical and Western blot studies demon-
strating the loss of dystrophin. Relatively few have been
studied at the molecular level, with mutations largely par-
alleling the deletions, insertions, and splice-site mutations
seen in DMD [70, 96–105].
The classification of canine dystrophinopathies is com-
plicated by the tendency to associate DMD and BMD
with severe and mild clinical phenotypes, respectively.
All canine DMD deletions described to date have been
out-of-frame, which would predict a severe DMD
phenotype. As discussed above and further below, des-
pite having an out-of-frame mutation, GRMD dogs may
stabilize and live well into adulthood [75]. The GRMD
phenotype could be influenced by spontaneous alterna-
tive splicing of the DMD transcript [106], with resultant
production of truncated partially functional dystrophin
isoforms expressed in so-called revertant fibers. Alterna-
tive splicing [107, 108] and revertant fibers [109] have
also been reported in DMD. Conditions in which trun-
cated isoforms of dystrophin are expressed have been
reported in Japanese Spitz and Labrador retriever canine
breeds. A 5.4-Mb fragment of the X chromosome is
inverted at the level of intron 19 of the DMD gene and
the retinitis pigmentosa GTPase regulator (RTGP) gene
of Japanese Spitz dogs [99]. Transcription was demon-
strated at the 5′ end but not beyond. A truncated 70–
80 kDa protein, consistent with aberrant expression of
Dp71 dystrophin-related protein, was identified. Baron-
celli et al. described a 3-year-old male Labrador retriever
with what was termed a Becker type syndrome [110].
The dog had a mild phenotype, normal serum CK, and
Fig. 5 Canine dystrophin protein (Ensembl protein ID ENSCAFP00000031637), with mutation information for 10 dog breeds with dystrophinopathies.
The breeds are Pembroke Welsh Corgi [98], Labrador retriever [97], Tibetan terrier [97], Cocker spaniel [97], golden retriever [96], Japanese Spitz [99],
Norfolk terrier [100], German shorthaired pointer [101, 102], two distinct mutations in the Cavalier King Charles spaniel [103, 104], and Rottweiler [105]. CH
indicates actin-binding calponin homology domains. The “WWP” domain binds proline-rich polypeptides and is the primary interaction site for dystrophin
and dystroglycan. EF indicates members of the EF-hand family domain that stabilizes the dystrophin-dystroglycan complex. ZNF represents a putative
zinc-binding domain, ZnF_ZZ is present in dystrophin-like proteins and may bind to calmodulin. All 79 exons are represented. Exons and protein domains
are approximately shown to scale. Insertion and deletion mutations are shown above the exons. At the bottom of the figure, the German shorthaired
pointer (GSHP) DMD gene deletion and point mutations are identified with a hatched line and arrows, respectively. Modified from reference [70]
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widespread immunohistochemical evidence of dys-
trophin expression. Immunoblotting revealed two bands
consistent with rod-domain and carboxyl-terminus frag-
ments. The molecular mutation was not identified.
Similarly, in another report, Labrador retrievers with no
dystrophin had increased serum CK and dystrophic lesions
on biopsy but no clinical evidence of myopathy [111]. A
somewhat analogous situation exists in German Short-
haired pointers that have a relatively mild phenotype even
through the entire DMD gene is deleted [101, 102, 112].
Genetic mechanisms other than frame shift must underlie
milder (or more severe) phenotypes in dystrophic dogs. A
mild phenotype in two so-called escaper GRMD dogs from
one of the Brazilian colonies was associated with a G>T
mutation in the promoter region of the Jagged1 gene [113].
Given that this substitution was apparently introduced by
an outcross, the Jagged1 mutation would not necessarily be
found in other GRMD colonies. We routinely see mildly
affected GRMD dogs that live beyond 3 years of age. In
testing done to date, none of these dogs have had the
Jagged1 mutation. Importantly, the original founder dog
for all GRMD dogs worldwide, Rusty, lived until 6 years
when he developed congestive heart failure and was eutha-
nized [86, 87]. Using Rusty as a benchmark, the GRMD
phenotype actually appears to have worsened over time,
potentially due to excessive inbreeding and concentration
of the effects of genetic modifiers. The genetic basis of
phenotypic variation is a subject of active research in my
laboratory, with a recent genome wide association study
(GWAS) identifying several potential candidate genes that
could influence disease phenotype [114].
With the advent of molecular therapies, particular
interest has been focused on certain so-called hot spot
areas at exons 3-7 and 45-53 of the DMD gene (see
above). In GRMD and the further outbred condition, ca-
nine X-linked muscular dystrophy in Japan (CXMDJ)
[115], an mRNA processing error results from a single
base change in the 3′ consensus splice site of intron 6.
Exon 7 is consequently skipped during mRNA process-
ing [96]. The resulting transcript predicts that the
dystrophin reading frame will be terminated within its
N-terminal domain in exon 8. The dystrophin reading
frame can be reestablished using antisense oligonucleo-
tides that target exons 6 and 8 [42, 116]. With regard to
the even more clinically relevant exon 45-53 hot spot
area, Cavalier King Charles spaniels have a G-T missense
mutation in the 5′ consensus splice site of intron 50 that
results in deletion of exon 50 [103]. Antisense
oligonucleotide-mediated skipping of exon 51 restored
the reading frame and protein expression in cultured
myoblasts from an affected dog. As mentioned above,
the fascinating DMD gene deletional mutation in the
German Shorthaired pointer breed bears particular men-
tion. The entire DMD gene is deleted in affected dogs
[101, 102], thus eliminating the possibility of alternative
splicing and the confounding effects of revertant fibers.
GRMD in preclinical trials: overview
Rather than repeat recent reviews of GRMD preclinical
trials and biomarkers [77, 97], this discussion will focus
on three areas: (a) the overall preclinical approach to
DMD treatment development; (b) nuances of GRMD
disease progression that must be considered in experi-
mental design; and (c) cautionary lessons learned from
prior GRMD treatment studies.
The DMD research community is fortunate to have
two well-defined genetically homologous animal models
that can be used in tandem to advance therapy develop-
ment. Mdx mice should logically be employed for initial
in vivo preclinical experiments. Studies that fail to dem-
onstrate potential efficacy bode poorly for translation of
the therapeutic strategy to humans and could provide a
logical “stopping point” for continued development. Al-
ternatively, if mdx findings are encouraging, consider-
ation should be given to extending the work to GRMD
or another canine model. However, in reality, studies in
dogs are limited because of their availability and ex-
pense. When dystrophic dogs have been studied, results
from mdx mice have not been consistently reproduced.
In such cases, inherent species differences preclude say-
ing whether the mouse or dog would better predict the
ultimate outcome in humans. But, at the very least, a
failure to reproduce favorable data in both species
should raise concerns and prompt reassessment of the
therapeutic approach.
The experimental design and outcome parameters
used in preclinical trials should mirror those anticipated
in human studies. Importantly, in the context of the
“two cultures phenomenon” discussed above, animal
studies should be rigorous, with close attention to issues
such as group size, use of proper controls, and blinding.
In a recent review of mdx and GRMD preclinical trials
[77], we offered the following guidelines for improving
translation of animal findings to humans:
 Design studies with sample sizes that are sufficiently
powered to detect treatment effects with the
outcome parameters used.
 Follow randomization and blinding procedures,
including who is blinded and when.
 Provide details of the statistical methods used for
data analysis and report all the results for each
analysis.
 Develop reliable and sensitive primary and
secondary endpoints for the animal model used.
 Independently validate treatment efficacy results in
another laboratory.
Kornegay Skeletal Muscle  (2017) 7:9 Page 10 of 21
 Validate treatment efficacy in two species (e.g., mdx
mouse and GRMD dog for DMD) whenever possible.
GRMD in preclinical trials: experimental design
For the sake of GRMD trials, we have long focused on
the 3- to 6-month age period during which clinical signs
progress particularly rapidly. Based on an epidemiologic
study by Patronek et al. [117], the first year of a golden
retriever’s life roughly equates to 20 years of a human.
Therefore, the GRMD age quartiles of 0–3, 3–6, 6–9,
and 9–12 months would logically correspond to 0–5, 5–
10, 10–15, and 15–20 years of DMD. In comparing the
relative severity of disease over these age periods,
GRMD and DMD generally progress analogously up to
6 months (GRMD) [75] and 10 years (DMD) [118, 119]
(Fig. 6). While GRMD pups may be weak at birth and
require dietary supplementation [120], they tend to
stabilize around 2 weeks and are mildly affected up to
3 months, when more progressive clinical involvement is
seen. Similarly, DMD boys have relatively stable disease
up to 6 years of age and then progressively decline for
the next 5 years [118].
In our experience, the GRMD and DMD phenotypes
diverge after 6 months and 5 years, respectively, with
dystrophic dogs tending to stabilize and boys inexorably
progressing [75, 118–130]. Even though GRMD dogs in
our colony progress markedly up to 6 months, they
rarely lose the ability to walk, which would be analogous
to becoming confined to a wheelchair in DMD, and
often live well into adulthood. With this said, other la-
boratories have reported a more severe GRMD pheno-
type. For instance, ~25% of GRMD dogs produced in
the colony at Alfort in France lose ambulation by
6 months [131]. In a similar vein, GRMD dogs in the
Brazilian colony directed by Mayana Zatz generally die
within the first 2 years of life [113]. Notably, both the
French and Brazilian colonies were derived from the same
founder dog, Rusty (see above), identified by our group in
1981. This distinction in phenotypic severity likely occurs
due to the relative role of genetic modifiers in each colony,
potentially being concentrated by inbreeding or intro-
duced by outbreeding. As an example, inbreeding tends to
worsen the phenotype of GRMD pups [120].
Planning and interpretation of (pre)clinical trials in both
DMD and GRMD is confounded by variable disease pro-
gression among individuals. As with the differing pheno-
types seen in GRMD colonies, DMD phenotypic variation
likely occurs due to genetic modifiers. Polymorphisms in
two genes, secreted phosphoprotein 1 (SPP1) (osteopontin)
and latent transforming growth factor β binding protein 4
Fig. 6 Comparative disease course of GRMD based on the relative equivalency of the first year of a golden retriever’s life and initial 20 years of a
human’s. The two periods are divided into quartiles, e.g., 0–3 months of GRMD paralleling 0–5 years of DMD, with signs of the skeletal myopathy
(SM) and cardiomyopathy (CM) listed for each period [118–130]. Note, the GRMD clinical course from 0–6 months largely parallels that of DMD
over the 0–10 year period. However, the GRMD and DMD phenotypes then dramatically diverge, with GRMD dogs often stabilizing and DMD
continuing to progress. SM skeletal myopathy, CM cardiomyopathy, LVEDV and LVSDV left ventricular end diastolic and systolic volumes, LVEF left
ventricular ejection fraction. Modified from reference [75]
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(LTBP4), have been shown to influence the DMD pheno-
type [132]. Per the discussion above, Vieira et al. identified
the Jagged1 gene as a modifier of the GRMD phenotype
[113]. We recently published results of a GWAS that de-
fined a number of genes associated with phenotype [114].
For local (intramuscular) or regional (single limb)
therapeutic approaches, the opposite untreated limb can
serve as a control. With systemic treatments, it is diffi-
cult to distinguish a treatment effect from inherently
mild clinical disease. Speaking generally, the number of
subjects required to establish benefit tracks directly with
the standard deviation of the outcome parameter being
used and inversely with the relative benefit anticipated.
In a somewhat sobering review, Brooke et al. concluded
that for a DMD clinical trial intended to “test a drug
which might slow the disease to 25% of its original rate
of progression, two groups (placebo and treatment) of
40 patients each would have to be followed for a year”
[118]. Such a study typically determines the longitudinal
effect of a treatment by comparing baseline and end-of-
study values. This helps to remove the confounding ef-
fect of phenotypic variation because each individual es-
sentially becomes his own control. In principle, even
more cases would be required if only data from a final
outcome parameter were compared between control
and treatment groups.
Power analysis has been used on a limited basis to as-
sess GRMD preclinical biomarkers, with only tibiotarsal
joint (TTJ) tetanic torque and the 6-minute walk test
(6MWT) being evaluated. The power analysis in our
TTJ study anticipated that a single measurement would
be done at the end of treatment and compared with a
value from a control group [130]. Data for TTJ tetanic
flexion torque showed that groups of 15 and 5 GRMD
dogs would be necessary to demonstrate differences of
0.2 and 0.4 at 6 months, with associated powers of 0.824
and 0.856. Based largely on these natural history data,
we have typically included 5 or 6 dogs in our GRMD
preclinical trials. However, the natural relative recovery
of TTJ flexion torque between 3 and 6 months compli-
cates its use in GRMD preclinical trials [130]. Extension
values decline over this same period but tend to vary
more markedly among dogs, necessitating larger group
sizes to establish significance. With more careful moni-
toring of inbreeding coefficient for sire-dam pairs in our
colony, the overall GRMD phenotype is now less severe
and not as variable as it was at the time the TTJ torque
data were published [130]. A subsequent trial of prednis-
one in GRMD dogs demonstrated therapeutic benefit of
~60% (p < 0.05) for extension torque using groups of 6
treated and 10 untreated GRMD dogs [133].
For sake of the 6MWT, GRMD dogs walked signifi-
cantly shorter distances than normal littermates at 6 and
12 months, generally supporting its use in preclinical
trials [134]. We also determined that percent increase in
CK after the 6MWT was higher in GRMD versus nor-
mal dogs, providing an additional potential biomarker.
With this said, neither the 6MWT nor CK percent
increase was particularly sensitive. Assuming a group
size of 6 each for treated and control GRMD dogs,
power analysis revealed that an 80% increase in mean
height-adjusted distance walked or 55% decrease in
mean post-exercise CK would be necessary to achieve a
desired power of 80%.
As with longitudinal DMD trials, a GRMD study com-
paring values at baseline (3 months) and end of treat-
ment (6 months) would lessen the effects of phenotypic
variation, reducing the number of dogs required. Ideally,
treatment groups would also be balanced between mildly
and severely affected individuals, based on an early bio-
marker that tracks with disease. In a GRMD study
focused on identification of early disease biomarkers, in-
creased numbers of a subset of circulating T cells and
decreased stride frequency on accelerometry at 2 months
strongly associated with more severe clinical disease at
6 months [131]. While independent control groups for
each preclinical trial should ideally be assessed, budget-
ary and animal number limitations may necessitate the
use of natural history controls. In one such study, TTJ
extensor torque and other indices were improved in six
GRMD dogs treated with a nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) inhibitor
compared to an independent control group [135].
Just as the overall disease course for DMD patients and
GRMD dogs varies, individual muscles also have different
patterns of progression. Proximal muscles are classically
affected in DMD, with further selective involvement of ex-
tensors versus flexors. Muscles, such as the quadriceps,
that undergo eccentric contraction are particularly vulner-
able [136]. Differential muscle involvement was well illus-
trated in our natural history TTJ torque study, with
flexors being preferentially affected at 3 months and ex-
tensors at 6 months [130]. Pointing to the challenges one
faces in analyzing functional data, the prednisone-treated
GRMD dogs discussed above had a paradoxical decrease
in flexor torque. This presumably occurred because of a
reduction in early necrosis that otherwise would have led
to functional flexor hypertrophy [133]. A similar decrease
in flexor torque was seen in another study of GRMD dogs
treated with prednisone and cyclosporine [137].
The pattern of differential involvement among skel-
etal muscles extends to the heart, which has a much
later onset of clinical disease. Reasons for preferential
disease of skeletal muscles or sparing of the heart are
unclear but likely also involve different patterns of
gene expression. Through a collaboration with investi-
gators at Vanderbilt, we showed that brain-derived
neurotropic factor (BDNF) is preferentially increased in
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young GRMD dogs, perhaps in keeping with a palliative
cardiac effect. Moreover, BDNF levels tracked with in-
creased ejection fraction in DMD patients [138]. The rela-
tively late onset of cardiac dysfunction complicates
preclinical GRMD studies done over the 3- to 6-month
age period. Definition of cardiac biomarkers that would
distinguish early subclinical disease is an active area of in-
vestigation for my laboratory.
Results of DMD [118] and GRMD [120, 139] func-
tional tests track and correlate with each other, provid-
ing some assurance that they are valid markers of
disease and can be used to document benefit. For sake
of GRMD, mildly affected dogs have proportionally lar-
ger TTJ angles and tetanic extensor torque. In addition,
cranial sartorius circumference measured at the time of
surgical biopsy is proportionally smaller. The opposite
pattern is seen in severely affected dogs. On the other
hand, 6MWT results from a much smaller group of
GRMD dogs did not correlate with other tests, causing
concern about this test’s reliability [134].
GRMD in preclinical trials: cautionary lessons
Pharmacologic approaches
In developing drug therapies for DMD, approaches have
been based on somewhat intuitive assumptions that tar-
geting secondary effects of dystrophin loss, like inflam-
mation, myofiber necrosis, and muscle atrophy, would
have benefit. While such treatments are logical, they may
inherently compromise or augment ongoing homeostatic
mechanisms and potentially do more harm than good.
Studies in the GRMD dog have sometimes brought side
effects into clearer focus, potentially allowing the particu-
lar treatment to be modified.
Anti-inflammatories Glucocorticoids, such as prednis-
one, have become the standard of care for DMD [140, 141],
but also cause a range of side effects [140, 142]. We were
motivated to study the effects of prednisone in GRMD dogs
to establish a baseline for comparing other treatments and
to explore alternative dosage regimens that might not be
practical in DMD. The study employed a variation of what
has become our standard approach to preclinical studies,
with dogs being dosed daily from 2 to 6 months of age at
either 1 or 2 mg/kg [133]. While this dose is higher than
the typical regimen of 0.75 mg/kg/day used in DMD
[140, 141], care must be taken in extrapolating drug
dosages among species. Body surface area takes into
account variables such as drug metabolism and, there-
fore, offers a better guide than body weight in consid-
ering appropriate dosing [143]. Several functional and
histopathologic biomarkers were compared between
treated and control GRMD dogs at 6 months. Al-
though a dose-related increase in TTJ extensor force
was seen, there was a paradoxical decrease in flexor
values. The reduced flexor force was attributed to a
reduction in early necrosis and a less pronounced re-
generative response that would otherwise have led to
functional hypertrophy. Dogs in the 2 mg/kg group
also had dramatic myofiber mineralization, potentially
due to decreased clearing by macrophages. A subse-
quent GRMD study by another group of combined
prednisone, again at 2 mg/kg, and cyclosporine pro-
duced similar results [137]. The fact that high dose
prednisone has deleterious effects is not surprising and
consistent with broader side effects of the drug. The dif-
ferential effect on flexor and extensor function is more
concerning because of the potential that this could trans-
late to DMD patients. As discussed further below in sec-
tion “Myostatin inhibition”, treatments that cause
differential extensor and flexor muscle improvement or
decline could aggravate preexisting contractures and pos-
tural instability.
Prednisone acts, in part, by inhibiting the NF-κB sig-
naling pathway [144], which is activated in DMD [145].
Accordingly, this pathway has been targeted in preclin-
ical DMD studies. We conducted a GRMD trial that
built on prior mdx mouse experiments in which the
Nemo Binding Domain (NBD) peptide was used to in-
hibit NF-κB signaling [135]. As with the prednisone
study, treatment began at 2 months of age and extended
for 4 months, with dogs being dosed intravenously three
times weekly and studied at 6 months using several bio-
markers. Results paralleled those seen with prednisone,
in that TTJ extensor force was increased in treated ver-
sus control dogs but flexor values were decreased. Of
greater concern, NBD administration over time led to
infusion reactions in both treated GRMD and wild-type
dogs, pointing to the potential for recombinant proteins
to induce an immune response.
Inhibition of protein degradation Given that DMD is
predominantly a muscle-wasting disorder, degradative
enzymes of the ubiquitin-proteasome (UPS) and calpain
systems have been targeted therapeutically. Promising
results have generally been achieved in the mdx mouse
with inhibition of the UPS [146] but not the calpain sys-
tem [147]. In a GRMD study, only about half of the
muscles studied had increased calpain activity and most
actually had decreased proteasome activity [148]. Of
greater concern, numerous UPS components were de-
creased in the heart, suggesting that pharmacologic in-
hibition of these systems in DMD could have
unintended deleterious consequences. Not surprisingly,
GRMD dogs treated with a novel calpain inhibitor did
not improve [149].
Myostatin inhibition Inhibition of the myostatin gene
(growth and differentiation factor 8), a key negative
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regulator of muscle growth [150, 151], offers another ap-
proach to reverse muscle atrophy. Mdx mice in which
myostatin was knocked out [152] or postnatally inhibited
[153] had a less severe phenotype. Data from normal
[154] and GRMD [155] dogs seemed to substantiate po-
tential value of myostatin inhibition. However, likely
reflecting feedback mechanisms, myostatin gene levels
are already markedly lower in DMD patients [156], mdx
mice [157], and GRMD dogs [139], raising questions
about whether further inhibition is desirable. Such con-
cerns were substantiated by a study in our colony in
which GRMD dogs were bred with whippets carrying a
myostatin gene mutation. We expected that myostatin
heterozygous GRMD dogs (GRippets) would have an im-
proved phenotype, consistent with the prior mdx work.
Surprisingly, the GRippets had more severe postural
changes than their dystrophic myostatin-wild-type litter-
mates, apparently due to differential effects on agonist
and antagonist muscles. For almost all muscles, the de-
gree of atrophy or hypertrophy in GRMD dogs was more
pronounced in the GRippets (Fig. 7) [158]. In keeping
with studies showing that myostatin is already downreg-
ulated in GRMD, mRNA and protein levels did not dif-
fer between the two groups. For sake of interpreting
these data, it is critical to recognize that findings from a
study in which myostatin was downregulated in utero
will not necessarily extrapolate to postnatal treatments.
But, these findings emphasize that the dystrophic body
is already motivated to downregulate myostatin and that
the effects of inhibition on muscle mass will not neces-
sarily be uniform.
Cell therapies
Therapies using muscle-derived or pluripotent stem cells
provide a direct means to replace muscle. Because of
their outbred nature, dogs are more likely than mice to
model the immune response to cell-based therapies.
Indeed, as discussed further below, the dog has proven
superior to even primates in modeling host versus graft
disease in bone marrow transplantation. Thus far, the
most notable stem cell approach for DMD involved
intramuscular transplantation of satellite cell-derived
myoblasts from normal individuals into dystrophic mus-
cles. Based on proof of principle studies in the mdx
mouse [159], several human trials were instituted, with
largely disappointing results [160, 161]. Most trans-
planted cells probably died due to the combined effects
of poor blood supply and immune rejection; those that
survived demonstrated limited migration [162–164]. We
characterized canine myoblasts [165] and conducted
analogous transplantation studies in the GRMD model
during the 1990s. Presumably because of these same
limitations, little implantation of donor cells was demon-
strated. Failed translation from mice to humans (and dogs)
may have related to variables influenced by scale, such as
cell migration [78]. With this lack of success in GRMD, we
developed a separate model system, in which muscles of
normal dogs were injected with a mix of myoblasts and the
toxin notexin. While myoblast implantation and differenti-
ation was achieved, providing some hope for the overall
approach, further studies have not been done [166].
Given the early disappointing results of myoblast trans-
plantation and the inherent limitations of localized cell
therapy to achieve meaningful benefit, considerable inter-
est has focused on other stem cells that could potentially
be delivered systemically. Bone marrow transplantation
was a natural candidate, and initial findings were encour-
aging. In two separate studies from Gussoni et al., dys-
trophin expression and donor-derived myonuclei were
demonstrated in transplanted mdx mice [167] and a
DMD patient who received a bone marrow transplant for
concomitant severe combined immune deficiency [168].
Nonetheless, in a follow-up study using the mdx4cv mu-
tant that lacks revertant fibers, myofiber dystrophin
Fig. 7 Averaged MRI segmentation of dogs with variable GRMD and myostatin (Mstn) genotypes. T2-FS MRI images of pelvic limb muscles in the
transverse plane at the level of the midthigh are shown in non-dystrophic control (a), dystrophic GRMD, wild-type Mstn+/+ (b) and GRMD, heterozygous
null Mstn+/− (GRippet) (c) dogs. Note the proportional enlargement of the sartorius and hamstring muscles and the associated atrophy/hypoplasia of the
quadriceps femoris of the GRMD, wild-type Mstn+/+ dogs, relative to the non-dystrophic control dogs, and the even more dramatic differential size of
these muscles in the GRippet Mstn+/− dogs. From reference [158]
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expression never exceeded 1% over the 10-month post-
transplant period [169].
As noted above, normal dogs have played a major role
in the development of bone marrow transplantation as a
reliable therapy, with many of the pioneering studies be-
ing done at the Fred Hutchinson Cancer Research Cen-
ter in Seattle [170]. Thus, the Seattle group was
particularly well situated to explore the utility of bone
marrow transplantation in dogs with muscular dys-
trophy. To this end, GRMD/CXMD carriers from the
University of Missouri and Cornell were used to estab-
lish a colony in Seattle. In a subsequent study, dys-
trophic dogs with allogenic bone marrow engraftment
did not have increased dystrophin-positive fibers, wild-
type dystrophin RNA, or donor-derived myonuclei [171].
Although results of bone marrow transplantation have
thus far been disappointing, other stem cell therapies
have been more encouraging. The GRMD model has
been increasingly utilized in these studies, with generally
positive findings being reported in 2016, alone, for
mesoangioblast [172], adipose mesenchymal [173], and
muStem [174] cells. Despite these promising results,
analogous studies have not yet been translated to DMD
patients [175]. Much as with bone marrow transplant-
ation, the dog’s outbred nature has been ideal for defin-
ing potential immunologic adverse effects. Considering
that myoblasts may elicit an immune response due to both
major histocompatibility complex (MHC) and non-MHC
antigens [176], most stem cell studies in dystrophic dogs
have employed immunosuppressive regimens. Findings
from these studies have been confounded by the potential
for anti-inflammatories to have an independent beneficial
effect. This conundrum arose in a 2006 study in which
GRMD dogs treated systemically with mesodermal stem
cells derived from the vascular wall, so called mesoangio-
blasts, had dystrophin expression [177]. Functional
improvement in these dogs was questioned, given that the
benefit could have occurred due to immunosuppression
[178]. Indeed, in a follow-up report, GRMD dogs treated
with cyclosporine and prednisone alone had analogous
improvement [137]. Another study of MuStem cells con-
trasted functional outcome variables in immunosup-
pressed and control dogs and found that dogs treated with
stem cells had greater therapeutic benefit [179].
Due to the confounding effect of anti-inflammatory
drugs, some subsequent stem cell studies in dystrophic
dogs have foregone immunosuppression, choosing instead
to match donor-recipient pairs for the canine MHC, the
dog leukocyte antigen [173, 180, 181]. Cell implantation
and at least minimal dystrophin expression have been
achieved in these dogs, with minimal or no adverse im-
munologic response. Another recent study offers an add-
itional cautionary note [182]. Non-immunosuppressed
GRMD dogs were treated three times intra-arterially with
autologous CD133+ cells engineered with a lentivirus cas-
sette to skip exons 6-8 and, thereby, restore the mRNA
reading frame. Timed function biomarkers stabilized or
improved in treated versus control GRMD dogs until the
third injection, after which a precipitous decline was seen.
This deterioration was attributed to an adaptive im-
mune response aggravated by dystrophin acting as a
neoantigen, analogous to a reaction seen in a DMD
adeno-associated virus (AAV)-micro-dystrophin gene
therapy trial (see below).
Genetic therapies
Genetic therapies have included AAV-mediated insertion
of a truncated mini/micro-dystrophin to fit the vector’s
limited ~4.5 kb carrying capacity, antisense oligonucleo-
tides to induce exon skipping and reestablish the dys-
trophin reading frame, agents to read-through stop
codon mutations, and replacement of dystrophin at the
sarcolemma with surrogates such as utrophin. Studies in
the mdx mouse have generally demonstrated efficacy
and safety of these strategies. Some therapies have sub-
sequently been extended to the GRMD model, providing
further proof of concept [77, 97] (see discussion under
canine dystrophinopathies above). Data from dystrophic
dogs supported the antisense approach, and side effects
were not seen [116, 183–186]. But, even with supportive
mdx and GRMD preclinical data, human trials have thus
far been inconclusive [59, 60].
Therapies employing AAV-mini/micro-dystrophin con-
structs should, in principle, offer similar therapeutic
benefits and potential side effects as those employing
exon-skipping strategies. With that said, while supportive
data have again been demonstrated, greater safety concerns
have been identified. Initial alarm was caused when local-
ized (intramuscular) treatment elicited an immune re-
sponse to either AAV capsid antigen [187] or dystrophin
serving as a neoantigen [188] that could be blocked with
immunosuppression [189]. Providing encouragement, dys-
trophin expression was demonstrated after intramuscular
injection of an AAV-micro-dystrophin construct without
immunosuppression in a single dystrophic dog [190]. And,
in another study, immunosuppressed dystrophic dogs
treated by intramuscular injection with AAV-micro-
dystrophin had improved force and lower eccentric
contraction decrement (ECD) despite a nonspecific
lymphocytic infiltrate [191].
Interestingly, the immune response has generally been
less pronounced with subsequent regional limb and sys-
temic therapies, potentially because of a dilutional effect
on the causative antigen [97]. However, one GRMD dog
treated with AAV-mini/micro-dystrophin by regional
limb delivery by my group in collaboration with Xiao
Xiao at the University of North Carolina-Chapel Hill
had increased signal intensity on MRI compatible with
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edema 3 months after treatment, and the level of dys-
trophin expression was actually higher in the contralat-
eral limb (Kornegay JN and Xiao X, unpublished). This
likely reflected the combined effects of dampened dys-
trophin expression due to the immune response and
leakage at the tourniquet to allow systemic delivery.
Given the generally promising results of regional limb
delivery in GRMD dogs, phase 1-safety studies using sa-
line versus active construct have been completed in both
the lower [192] and upper [193] extremities of adult
muscular dystrophy patients, with minimal side effects.
Results of systemic AAV-mini/micro-dystrophin ther-
apy in dystrophic dogs have been mixed. On the one
hand, our group and others have demonstrated long-
term dystrophin expression, with [194] and without
[195] immunosuppression. But, one group of dogs that
we studied had delayed growth and pelvic limb muscle
atrophy and contractures, seemingly due to an innate
immune response (Fig. 8) [195]. Moreover, clear evi-
dence of functional improvement akin to that seen in
GRMD dogs with the exon-skipping strategies [186] has
not been demonstrated after systemic therapy with AAV-
mini/micro-dystrophins, giving rise to persistent questions
about the ability of mini/micro-dystrophins to sustain
myofiber integrity when stressed by larger mammals.
Conclusions
Duchenne muscular dystrophy (DMD) is a devastating
X-linked disease for which ameliorative treatments are
desperately needed. As with other inherited conditions,
genetically homologous animal models are critical for
exploring DMD disease pathogenesis and the efficacy
and side effects of potential therapies. Until the DMD
gene and dystrophin protein were identified in the
1980s, putative animal models were chosen based on
similarities in the pattern of inheritance and common
phenotypic features. Golden retriever dogs with an ap-
parent X-linked degenerative myopathy, subsequently
termed golden retriever muscular dystrophy (GRMD),
were recognized in the 1970s and 1980s and shown to
have phenotypic features consistent with those of DMD.
These features, including elevated serum enzymes,
sarcolemmal defects, and CRDs on EMG, were in keep-
ing with the membrane theory of DMD disease patho-
genesis. One of these dogs, Rusty, identified at the
University of Georgia in 1981, was the founder for initial
colonies at Cornell University and NCSU. Subsequent
studies confirmed genetic homology with DMD, and
multiple additional colonies were established in the USA
and around the world. In a similar time frame, an add-
itional naturally occurring DMD genetic homologue, the
Fig. 8 T2-weighted MR images of GRMD pelvic limb muscles 16 weeks after AAV9-CMV-mini-dystrophin vector intravenous injection. Transverse
(left) and sagittal (right) images of two different dogs (dog 1: a, b, e, and f; dog 2: c, d, g, and h) are seen. The images in e–h have been segmented and
color-coded to outline individual muscles. Signal intense lesions that persisted with fat saturation, most likely representing fluid due to inflammation or
edema, are particularly pronounced in the vastus heads of the quadriceps and adductor muscles. From reference [195]
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mdx mouse, was identified and characterized. Extending
from these studies in the 1980s, the DMD research com-
munity has had these two well-defined genetically hom-
ologous animal models to use in tandem for therapy
development. However, neither of these models is com-
pletely analogous, with the mdx mouse displaying a mild
phenotype and the more severely affected GRMD dog
often stabilizing after 6 months of age. Advantages of
the mdx mouse relate to its consistent phenotype and
relatively modest expense, allowing multiple variables to
be tested through reasonably powered studies. On the
other hand, the mouse’s small size may limit assessment
of scalable variables such as cell migration or drug diffu-
sion. Perhaps even more importantly, preclinical studies
in mdx mice have generally not identified complications,
most notably immunologic side effects of gene and cell
therapies. These advantages and limitations are essen-
tially reversed for dystrophic dogs. The expense of ani-
mal housing and required facilities limits the number of
dogs that can be studied. Accordingly, multiple variables,
as with the use of immunosuppression, cannot always be
tested. Phenotypic variation further reduces the power
that can be achieved with GRMD trials. On the other
hand, the dog’s larger size and outbred nature allows for
better modeling of scalable variables such as cell diffu-
sion and the immune response to biologics. A general
paradigm has evolved, whereby initial testing is done in
mdx mice and, assuming positive results, follow-up stud-
ies are completed in dystrophic dogs. As with preclinical
studies more generally, findings from these animal
models have not consistently translated to DMD pa-
tients. Examples of failed translation include pharmaco-
logic approaches, the myoblast transplantation studies of
the 1990s, and the current uncertainty surrounding exon-
skipping strategies. A major factor in this lack of transla-
tion has been termed the “two cultures phenomenon,”
whereby experimental design in animal studies has not
consistently mirrored the rigor of human clinical trials,
with fundamental tenets such as appropriate powering of
outcome parameters and blinding not being sufficiently
considered. To address this ongoing problem, certain
basic standards should be adopted. Care should be taken
in planning the experimental design to ensure that sample
sizes are sufficiently powered to detect treatment effects
with the outcome parameters used; animals should be
randomly assigned to treatment and control groups, and
investigators should be blinded to which animals are
treated; statistical methods used in data analysis should be
carefully considered and reported; endpoints (biomarkers)
should largely follow those to be used in future DMD tri-
als and be studied in a natural history setting to allow ap-
propriate powering in advance of the preclinical trial;
results should be validated in another laboratory; and,
especially for treatments such as cell and gene therapies
that carry substantial risk, treatment efficacy and compli-
cations should be determined in both the mdx mouse and
GRMD dog. In this last instance, the role of animal
models in predicting side effects has often been over-
looked or deemphasized. Following on the premise that
physicians should first and foremost “do no harm,” pre-
clinical studies offer an opportunity to identify poten-
tial risks that can be corrected prior to human trials.
The GRMD model has played a particularly important
role in characterizing complications of pharmacologic
intervention and immunologic reactions to cell and
gene therapies.
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